The number of cases of diabetes worldwide has significantly increased in the last decade and it is expected to double by 2030 (1) . This "diabetic epidemic" also considerably affects pregnant women (2) . However, the management of pre-gestational and gestational diabetes, the latter being defined as glucose intolerance first detected in pregnancy, remains controversial (3) . Gestational and pre-gestational diabetes are associated with increased feto-maternal morbidity, including stillbirth, macrosomia, and fetal malformations, as well as long-term complications in the mother and offspring (4) (5) (6) . However, treatment and/or monitoring reduce perinatal mortality to the rate in the healthy population. There is no internationally agreed approach and there are neither up-to-date World Health Organization (WHO) recommendations nor fact sheets designed especially for diabetes in pregnancy. The complexity of gestational and pre-gestational diabetes, its underlying pathogenetic mechanism, and recent insights into potential and far-ranging complications have justified the establishment of a considerable number of recent national guidelines (7) . Variation in treatment strategies has originated from different views, approaches, and traditional management in obstetric clinics around the globe.
As a novelty, this study does not only compare national guidelines of Austria and Australia, two developed high-income countries situated on different continents, but also estimates the level to which physicians comply with their country's guidelines. Since currently no international standardized approach to screening criteria and diagnostic methods for gestational diabetes and pre-gestational diabetes exists and opinions differ even on the national level, we hypothesized that there were major differences in screening, diagnosing, and treating diabetes in pregnancy. An additional aim of this study was to produce a table of requirements that should be incorporated into future guidelines.
Methods
We systematically reviewed Austrian (ÖDG, Austrian Diabetes Society) and Australian guidelines (ADIPS, Australasian Diabetes in Pregnancy Society) on gestational and pregestational diabetes care (8) (9) (10) . Physicians in Austria (Department of Obstetrics and Gynecology at the Medical University of Graz) and Australia (Diabetes Center at the Mater Mother's Hospital in Brisbane) had at telephone conferences commonly agreed upon a set of components which should be used. These components were partly derived from a study by Cutchie et al (7) . Subsequently, a systemic guideline review was performed and the guidelines were reviewed by two physicians at the Austrian department and two physicians at the Australian department. The results of this review were communicated and discussed among these physicians at telephone conferences and via e-mail. Components contained both qualitative and quantitative data. Quantitative components for gestational diabetes were the following: abnormal oral glucose tolerance test values (mmol/L), abnormal values and number of abnormal oral glucose tolerance test figures necessary for diagnosis, monitoring/glucose targets (mmol/L), and the number of glucose measuring per day. Qualitative components for gestational diabetes were the following: institutions performing screenings, further management when abnormal oral glucose tolerance test is performed, further management and indications for insulin therapy, route and timing of delivery, and postpartum management and counseling. Quantitative components for pre-gestational diabetes were the following: management during the preconceptional period, target values for HbA1c and frequency of measuring, glu-cose target values (mmol/L), and the number of glucose measurements per day. Qualitative components for pre-gestational diabetes were the following: medical surveillance, obstetric surveillance, medication used, route and timing of delivery, and postpartum management and counseling.
Current practices at the two obstetric centers were assessed by interviewing key stakeholders and collating the available documentation. Key stakeholders were heads of the diabetic clinics in Austria and Australia and their two closest coworkers. They were asked to fill in the questionnaires. The results were reviewed by the same physicians who had reviewed the guidelines and the results were discussed at telephone conferences and via email. Both centers are tertiary centers, offering full obstetric and neonatal intensive care services, and are a centralized location with access to costly and complex medical related services (11) . The results of the centers were also compared with current guidelines in Austria and Australia, and lessons to be learned by comparing guidelines and current practices were highlighted. Following the discussions held during the process of assessment and data collection, a check-list was drawn up by the Austrian and Australian experts. This check-list should be used by agencies and research groups who wish to set up guidelines by listing all the necessary queries a practitioner might have when treating women with diabetes in pregnancy (Box 1 and Box 2).
Results
There are no official Austrian guidelines for pre-gestational diabetes (Table 1) . When quantitative components in gestational diabetes are concerned (Table 2) , Austrian guidelines and the Austrian center had different oral glucose tolerance test cut-off levels for diagnosing gestational diabetes and Austrian center had the lowest cut-off levels (fasting ≥5.0 mmol/L, 1 hour ≥8.9 mmol/L, 2 hours ≥7.8 mmol/L). Fasting glucose levels for monitoring gestational diabetes in the Austrian center were lower, 1-hour levels were higher, and 2-hour levels were equal to the Austrian guidelines. Optimal targets for self measured glucose in gestational diabetes were generally higher in Australia (center and guidelines) than in Austria. The Austrian obstetric center recommended more frequent blood glucose measurements in gestational diabetes patients (9 to 12 times daily) than the Australian center (4 times daily). When qualitative components of gestational diabetes are concerned (Table 2), the difference was that at the Austrian obstetric center oral glucose tolerance test was performed by general practitioners, obstetricians, and medical physicians and at the Australian obstetric center mostly by general practitioners. Two-stage screening for gestational diabetes was recommended by the Australian Diabetes in Pregnancy Society (50 g and 75 g), while one-stage screening was recommended by the Austrian guidelines and applied at the Austrian center. One-hour target levels after glucose intake in oral glucose tolerance test were not of any relevance in Australia (neither in guidelines nor at the center), while at the Austrian center the use of one-hour targets was recommended and applied. At the Austrian center, amniocentesis was recommended to make a decision on the start of insulin treatment in pregnant women with gestational diabetes. This approach was neither used in the Australian obstetric center nor recommended by any of the two guidelines.
A multidisciplinary approach for gestational diabetes and pre-gestational diabetes was specified in the Australian guidelines and put into practice at the Australian center. Austrian guidelines did not particularly mention the necessity of a multidisciplinary approach.
Timing of delivery was not determined in the Austrian guidelines for gestational diabetes management. The Austrian obstetric center continued pregnancy beyond term in uncomplicated and non insulin-treated gestational diabetes pregnancies, while the Australian center continued gestational diabetes pregnancies until term.
Australian guidelines considered certain ethnic groups as high risk and recommend the measurement of blood glucose levels more frequently in these ethnic groups post partum. Austrian guidelines did not mention differences in ethnic groups when managing gestational diabetes.
When quantitative components in pre-gestational diabetes are concerned (Table 1) , except for fasting glucose levels ranges, the Austrian obstetric center used the lowest glucose level targets in pre-gestational diabetes (after 1 hour <7.8 mmol/L and after 2 hours 6.7 Box 2. List of queries and topics that should be addressed when setting up guidelines for the screening, diagnosis, and management of pre-gestational diabetes mmol/L). The Austrian center recommended more frequent blood glucose measurements in pre-gestational diabetes patients (9 to 12 times daily) than the Australian obstetric center. When qualitative components in pre-gestational diabetes are concerned (Table 1) , we found that obstetric and medical surveillance in pre-gestational diabetes coincided broadly in both centers and the Australian guidelines. In preconceptional management of pre-gestational diabetes there were no variations in recommended dosage of folic acid in both centers and guidelines. However, the Australian guidelines and the Australian center recommended a multidisciplinary approach, whereas in Austria there was no multidisciplinary approach. Furthermore, the Austrian obstetric center used only human insulin, whereas the Australian center used insulin analogues and metformin for treatment in pre-gestational diabetes.
Discussion
Gestational and pre-gestational diabetes pose risks to the mother and developing fetus. There has been controversy about the importance of gestational diabetes and the need for universal screening. However, the clear benefits of treating women with gestational diabetes have been recently demonstrated by the Australian Carbohydrate Intolerance Study in pregnant women (ACHOIS) (12) .
Since at the time of this research there were no Austrian guidelines for pre-gestational diabetes, we strongly believe that such guidelines should be developed as a priority on national level. Representatives of the Austrian Diabetes Society recently stated that guidelines are under way and will be ready in 2007 (Personal Communication with members of the Austrian Diabetes Society, October 2006). In the absence of an internationally agreed approach to detection, diagnosis, and management of gestational diabetes and pre-gestational diabetes, we hypothesized that we might detect very controversial approaches in both countries. The main differences were the number of HbA1c measurements during pregnancy, the performance of screening, diagnosing and monitoring gestational and pre-gestational diabetes, self monitoring, the person performing oral glucose tolerance tests and screening, the type of glucose lowering agents used, timing of delivery and management during labor, the implementation of a multidisciplinary approach, and risk factors such as ethnicity.
Self monitoring and HbA1c measuring were performed more frequently in Austria than in Australia. Many studies have shown that an elevation of first trimester HbA1c above 7% is associated with an increased risk of fetal malformation (13) . However, there is also evidence that higher risk is also associated with any elevation of HbA1c above the reference range. This has led to the recommendations for an HbA1c target within the reference range whenever possible (14) .
There were markedly opposed views on screening and further management of gestational diabetes. The disagreement as to when and how to screen for gestational diabetes is present throughout the literature (15) . We showed that there was an agreement on the universal screening of all pregnant women and on the concept that one abnormal value in oral glucose tolerance test leads to the diagnosis of gestational diabetes; however there was disagreement in performing of the screening itself. In Austria (guidelines and center) a one-step screening test using 75 g glucose was recommended and put in practice, whereas Australian guidelines recommended a two-stage screening method: at stage one 50 g or 75 g (morning/non fasting) is used; if glucose levels are exceeded at stage one, a fasting test using 75 g glucose is performed. The 75 g glucose load for screening gestational diabetes has been endorsed by the World Health Organization (WHO) for use during pregnancy (16) and previous studies have shown an influence of previous meals on the 50 g glucose two-stage screening test (17). Other studies have showed that costs of one-stage or two-stage regimen are similar (18) . Therefore, one-stage fasting screening test with 75 g oral glucose should be preferred. Applying a one-stage or two-stage screening test and defining the cut-off glucose levels for the diagnosis of gestational diabetes are very important for determining the prevalence of gestational diabetes, as well as for perinatal and maternal outcomes on a national level. The latter will be more favorable when oral glucose tolerance test thresholds for gestational diabetes are lowered, as more near-normoglycemic pregnant women will be diagnosed with gestational diabetes. Hence, comparing gestational diabetes prevalences remains difficult as inclusion criteria are inconsistent. Although the findings of Australian Carbohydrate Intolerance Study in preg-nant women (ACHOIS) have suggested that universal screening should be implemented, the precise level of hyperglycemia that carries increased pregnancy risk remains to be defined (19) ; results of the blinded prospective international epidemiological Hyperglycemia and Adverse Pregnancy Outcome study (HAPO) which are expected by mid 2007 will hopefully identify a clear cut point or threshold for the complications associated with gestational diabetes (20) .
When it comes to diagnosing and monitoring gestational diabetes, the Austrian obstetric center appears to be recommending much lower glucose target levels and using amniocentesis extensively for insulin treatment decision making. At the same time, the Austrian obstetric center differs from its national guidelines. In fact, gestational diabetes management has been traditionally understood at the Austrian obstetric center on the basis of fetal hyperinsulinism resulting in diabetogenic fetopathy with associated consequences for the fetus (21, 22) . Amniocentesis is considered a reliable intervention to detect fetal hyperinsulinism at the Austrian center (23) . Furthermore, several studies have suggested that amniotic fluid insulin levels are a sensitive and representative fetal parameter and a direct measure of fetal metabolic control, independent of placental function (24, 25) . Amniocentesis in gestational diabetes pregnancies remains uncommon in other centers, as it poses a debatable invasive procedure. In addition, none of the published practice guidelines in English language, which have been approved by national agencies, considers amniocentesis as a routine procedure in management of gestational diabetes. Amniocentesis might be a worthwhile option, however further trials are needed for this diagnostic intervention.
Neither of the two guidelines has covered the topic of who should perform oral glucose tolerance tests and screening. At the Australian obstetric center, screening is mainly performed by general practitioners and standardized by a licensed laboratory, whereas at the Austrian obstetric center, oral glucose tolerance test screening is performed by obstetricians, medical physicians, or general practitioners. Some of the latter do not perform oral glucose tolerance tests in pregnancy on a regular basis, which leads to errors and adverse results. We suggest that regular training and permanent up-to-date information should be provided to all those who perform oral glucose tolerance tests and that the necessity of training should also be mentioned in guidelines.
The use of glucose lowering agents differs significantly in both centers. Whereas the Australian obstetric center uses insulin analogues, these agents are not thoroughly recommended by the Austrian guidelines and are not applied at the Austrian center. Insulin analogues are increasingly used instead of human insulin. Although evidence is emerging that the use of insulin analogues is not associated with excess risk of fetal malformations (26) , there are still no recommendations from any guidelines. Metformin is sometimes used at the Australian obstetric center in Type 2 diabetes only; however a randomized trial involving metformin (MiG study) is under way (27) .
Disagreement remains about the timing of delivery and management during labor in both pre-gestational and gestational diabetes. It appears that guidelines in gestational and pre-gestational diabetic pregnancy remain fairly non-specific when it comes to recommendations concerning the timing of delivery. This gap in international guidelines has also been identified by other authors in the past (7) . The optimal time of delivery in diabetes in pregnancy is rather hard to determine and will, even if broad international agreement among ante-and post-natal management are achieved, most likely remain a domain where individual co-factors and risks have to be balanced.
The optimal treatment of diabetes in pregnancy covers a broad range of areas and thus calls for a multidisciplinary approach (28) . A multidisciplinary approach is not fully applied at the Austrian obstetric center since endocrinologists and diabetologists are not involved in the management of diabetes in pregnancy at the obstetric department. The medical department at the Austrian center does treat cases of pre-gestational diabetes, but as no consensus concerning the management of diabetes in pregnancy has been established until now, close collaboration of obstetricians and medical physicians in treating gestational and pre-gestational diabetes remains absent. Thus, even within the same institution "professional opinion" may vary. The implementation of a multidisciplinary approach is crucial in every institution dealing with diabetes in pregnancy in the best interest of their patients. Although it is not particularly stated in the Austrian guidelines, it might be presumed that a multidisciplinary approach applies there, especially since these guidelines have been compiled by a multidisciplinary team. Guidelines should clearly mention the importance of a multidisciplinary approach and team members should be listed precisely.
There is a wide difference in the prevalence of diabetes in different ethnic groups, with the prevalence varying from the lowest in Africa to the highest in Europe and North America (29) . Gestational diabetes mellitus is known to reflect the incidence of type 2 diabetes in the background population and varies significantly with ethnicity (30). Migration of women from areas with ethnic high-risk groups for diabetes in pregnancy, like South Asia or the Middle East (31), has increased the observed prevalence in Western Europe and North American countries (32) . Despite the fact that Austria is not a traditional site for immigration, its official proportion of foreign-born residents in 2001 was even higher than that of the United States, reaching a level of 12.5% (33) . Nonetheless, the differences in ethnic groups have not been covered by the Austrian guidelines in gestational diabetes. We believe that guidelines should highlight certain ethnic groups as risk groups at the time of screening, as well as in the post partum management. At the same time, centers should be aware of the crucial differentiation of ethnicity and its impact on the prevalence of gestational diabetes in daily practice. Individual risk factors like obesity, family history of abnormal oral glucose test results, and diabetes in previous pregnancies also have to be taken into account and should be specifically mentioned in guidelines.
In conclusion, we found more variation in the management of gestational than pregestational diabetes. Although Austria and Australia are situated on two different continents their management in pre-gestational diabetes can be considered similar. The Australian center complies better with its national guidelines than the Austrian center. A general screening, preferably one-step screening, should be offered to each pregnant woman. We suggest that a multidisciplinary approach is crucial and that team members should be mentioned in guidelines. Variability in ethnicity should be covered by all guidelines, especially in countries where high-risk groups live or their further immigration is expected, and individual risk factors have to be considered. If management in a center deviates from national guidelines (ie, performance of amniocentesis), it should be reassessed and agreed upon by other research groups involved in the national guideline set up. Over-all screening of gestational diabetes represents the most divergent issue and remains to be further investigated. As long as screening tests and cut-off levels for diagnosis remain variable, interpretation and comparison of gestational diabetes prevalence will remain problematic. Our study showed that it was difficult to standardize the screening criteria and diagnostic methods for gestational and pre-gestational diabetes within a small country like Austria and even within the same institution. National and international consensus has yet to be achieved in the management of diabetes in pregnancy.
